

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE				Attorney Docket No.	50147/003002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.	Not Yet Assigned	
				Applicant	Larsen et al.	
				Filing Date	January 28, 2004	
				Group	Not Yet Assigned	
				IDS Filed	January 28, 2004	
(37 C.F.R. §1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass
MP	4,336,185	Jun. 22, 1982	Niswender			
MP	5,547,668	Aug. 20, 1996	Kranz et al.			
MP	5,698,178	Dec. 16, 1997	Goldenberg			
MP	6,077,499	Jun. 2000	Griffiths et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office		Class	Subclass
MP	0 282 057 A2	Sept. 14, 1988	Europe			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
MP	Bruland et al., "Expression and Characteristics of a Novel Human Osteosarcoma-Associated Cell Surface Antigen," <i>Cancer Res.</i> , 48:5302-5309 (1988).					
MP	Bruland et al., "New Monoclonal Antibodies Specific for Human Sarcomas," <i>Int. J. Cancer</i> , 38:27-31 (1986).					
MP	Bruland, "Cancer Therapy with Radiolabeled Antibodies. An Overview," <i>Acta Oncol.</i> , 34:1085-1094 (1995).					
MP	Campbell et al., "Folate-binding Protein Is a Marker for Ovarian Cancer," <i>Cancer Res.</i> , 51:5329-5338 (1991).					
MP	Fraker et al., "Protein And Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril," <i>Biochem. Biophys. Res. Comm.</i> , 80:849-857 (1978).					
MP	Larsen et al., "Inactivation of Human Osteosarcoma Cells <i>In Vitro</i> by ²¹¹ At-TP-3 Monoclonal Antibody: Comparison with Astatine-211-Labeled Bovine Serum Albumin, Free Astatine-211 and External-Beam X Rays," <i>Radiat. Res.</i> , 139:178-184 (1994).					
MP	Larsen et al., "Preparation and Quality Control of ²¹¹ At-Labelled and ¹²⁵ I-Labelled Monoclonal Antibodies. Biodistribution in Mice Carrying Human Osteosarcoma Xenografts," <i>J. Labelled Compds. Radiopharmaceuticals</i> , 34:773-785 (1994).					
MP	Larsen et al., " α -Particle Radiotherapy with ²¹¹ At-Labelled Monodisperse Polymer Particles, ²¹¹ At-Labelled IgG Proteins, and Free ²¹¹ At in a Murine Intraperitoneal Tumor Model," <i>Gynecol. Oncol.</i> , 57:9-15 (1995).					
MP	Mathias et al., "Indium-111-DTPA-Folate as a Potential Folate-Receptor-Targeted Radiopharmaceutical," <i>J. Nucl. Med.</i> , 39:1579-1585 (1998).					
MP	Reddy et al., "Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 15:587-627 (1998).					
MP	Shinoda et al., "In Vivo Fate of Folate-BSA in Non-Tumor- and Tumor-Bearing Mice," <i>J. Pharm. Sci.</i> , 87:1521-1526 (1998).					
MP	Trippett et al., "Therapeutic Strategies Targeting Proteins that Regulate Folate and Reduced Folate Transport," <i>J. Chemotherapy</i> , 11:3-10 (1999).					
EXAMINER			DATE CONSIDERED			
/Melissa Perreira/			06/19/2006			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						